Two Sigma Advisers’s Harvard Bioscience HBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-87,856
Closed -$588K 927
2025
Q4
$588K Buy
87,856
+63,540
+261% +$377K ﹤0.01% 1719
2025
Q3
$107K Buy
24,316
+19,631
+419% +$93.1K ﹤0.01% 2219
2025
Q2
$20.8K Sell
4,685
-8,871
-65% -$37.1K ﹤0.01% 2289
2025
Q1
$76.7K Buy
13,556
+10,700
+375% +$137K ﹤0.01% 2276
2024
Q4
$60.3K Sell
2,856
-1,140
-29% -$26.2K ﹤0.01% 2270
2024
Q3
$107K Sell
3,996
-3,570
-47% -$105K ﹤0.01% 2159
2024
Q2
$216K Sell
7,566
-1,250
-14% -$43.8K ﹤0.01% 2182
2024
Q1
$374K Sell
8,816
-1,710
-16% -$76.9K ﹤0.01% 1988
2023
Q4
$563K Sell
10,526
-7,980
-43% -$360K ﹤0.01% 1867
2023
Q3
$796K Buy
18,506
+6,020
+48% +$278K ﹤0.01% 1615
2023
Q2
$685K Buy
12,486
+3,330
+36% +$183K ﹤0.01% 1688
2023
Q1
$385K Sell
9,156
-6,120
-40% -$182K ﹤0.01% 2045
2022
Q4
$423K Sell
15,276
-6,048
-28% -$149K ﹤0.01% 1946
2022
Q3
$546K Buy
21,324
+5,658
+36% +$187K ﹤0.01% 1809
2022
Q2
$564K Sell
15,666
-1,030
-6% -$46.5K ﹤0.01% 1857
2022
Q1
$1.04M Sell
16,696
-8,420
-34% -$498K ﹤0.01% 1620
2021
Q4
$1.77M Sell
25,116
-4,880
-16% -$347K ﹤0.01% 1259
2021
Q3
$2.09M Sell
29,996
-230
-0.8% -$18.3K 0.01% 1226
2021
Q2
$2.52M Buy
30,226
+13,370
+79% +$946K 0.01% 1186
2021
Q1
$920K Buy
16,856
+2,750
+19% +$134K ﹤0.01% 1701
2020
Q4
$605K Buy
14,106
+5,140
+57% +$192K ﹤0.01% 1795
2020
Q3
$270K Buy
8,966
+210
+2% +$7.06K ﹤0.01% 2055
2020
Q2
$271K Sell
8,756
-180
-2% -$4.85K ﹤0.01% 2161
2020
Q1
$197K Sell
8,936
-1,320
-13% -$35.8K ﹤0.01% 2174
2019
Q4
$313K Sell
10,256
-3,130
-23% -$90.1K ﹤0.01% 2051
2019
Q3
$412K Buy
13,386
+6,620
+98% +$165K ﹤0.01% 1787
2019
Q2
$135K Buy
6,766
+4,440
+191% +$130K ﹤0.01% 2185
2019
Q1
$100K Sell
2,326
-20
-0.9% -$725 ﹤0.01% 2192
2018
Q4
$75K Sell
2,346
-240
-9% -$9.46K ﹤0.01% 2245
2018
Q3
$136K Buy
2,586
+262
+11% +$14.7K ﹤0.01% 2131
2018
Q2
$124K Sell
2,324
-92
-4% -$4.71K ﹤0.01% 2257
2018
Q1
$121K Sell
2,416
-20
-0.8% -$897 ﹤0.01% 2210
2017
Q4
$80K Sell
2,436
-20
-0.8% -$675 ﹤0.01% 2169
2017
Q3
$92K Sell
2,456
-50
-2% -$1.48K ﹤0.01% 2120
2017
Q2
$64K Hold
2,506
﹤0.01% 2198
2017
Q1
$65K Sell
2,506
-200
-7% -$5.76K ﹤0.01% 2298
2016
Q4
$83K Sell
2,706
-10
-0.4% -$254 ﹤0.01% 2278
2016
Q3
$74K Sell
2,716
-330
-11% -$9.16K ﹤0.01% 2153
2016
Q2
$87K Sell
3,046
-90
-3% -$2.86K ﹤0.01% 1981
2016
Q1
$95K Sell
3,136
-180
-5% -$5.1K ﹤0.01% 1944
2015
Q4
$115K Buy
3,316
+1,000
+43% +$34.2K ﹤0.01% 1756
2015
Q3
$88K Buy
2,316
+120
+5% +$5.58K ﹤0.01% 1728
2015
Q2
$125K Sell
2,196
-230
-9% -$13.1K ﹤0.01% 1795
2015
Q1
$141K Hold
2,426
﹤0.01% 1770
2014
Q4
$138K Sell
2,426
-664
-21% -$31.6K ﹤0.01% 2287
2014
Q3
$126K Sell
3,090
-640
-17% -$29.4K ﹤0.01% 2198
2014
Q2
$170K Buy
3,730
+1,650
+79% +$69.3K ﹤0.01% 2301
2014
Q1
$98K Buy
2,080
+800
+63% +$36.4K ﹤0.01% 2170
2013
Q4
$60K Sell
1,280
-408
-24% -$17.8K ﹤0.01% 2236
2013
Q3
$68K Buy
1,688
+263
+18% +$10.3K ﹤0.01% 2032
2013
Q2
$51K Buy
+1,425
New +$54.6K ﹤0.01% 2112

Other funds holding HBIO

Two Sigma Advisers's HBIO Position: Q1 2026 in Review

Two Sigma Advisers sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 87,856 shares — an estimated $588K sold.

Two Sigma Advisers first reported a position in HBIO in Q2 2013 and held it in 51 quarters. The position peaked at $2.52M in Q2 2021. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

  • Two Sigma Advisers reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 87,856 Harvard Bioscience shares in Q1 2026, an estimated $588K.
  • Two Sigma Advisers first reported a position in Harvard Bioscience in Q2 2013 and held it in 51 quarters.
  • Two Sigma Advisers's Harvard Bioscience position peaked at $2.52M in Q2 2021.
  • 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.